Research in hemophilia is ongoing, with a focus on improving treatments and finding a cure. Gene editing technologies, such as CRISPR/Cas9, hold promise for correcting the underlying genetic mutations. Additionally, advancements in biotechnology aim to develop longer-lasting and more effective clotting factor products.
